News
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...
4d
Zacks Investment Research on MSNRXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...
Subtle differences in an mRNA sequence enables a ribosome to produce more or less of a certain protein. A new AI model called ...
5d
TipRanks on MSNBB Biotech Outperforms Nasdaq Biotech Index in Q2 2025An update from BB Biotech ( ($CH:BION) ) is now available. In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in ...
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...
Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...
Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...
Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results